Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

10.1158/1078-0432.CCR-08-0509

Saved in:

Bibliographic Details
Main Authors:	Huynh, H, Ngo, V.C, Fargnoli, J, Ayers, M, Khee, C.S, Heng, N.K, Choon, H.T, Hock, S.O, Chung, A, Chow, P, Pollock, P, Byron, S, Tran, E
Other Authors:	MEDICINE
Format:	Article
Published:	2020
Subjects:	basic fibroblast growth factor brivanib alaninate caspase 3 CD31 antigen fibroblast growth factor receptor 1 Ki 67 antigen mitogen activated protein kinase 1 mitogen activated protein kinase 3 protein kinase B vasculotropin vasculotropin receptor 2 alanine drug derivative fibroblast growth factor receptor triazine derivative vasculotropin receptor animal experiment animal model animal tissue antiangiogenic activity antiangiogenic therapy antineoplastic activity apoptosis article cancer inhibition cancer model cell proliferation cell strain HepG2 controlled study down regulation drug mechanism drug sensitivity enzyme inhibition human human cell human tissue liver cell carcinoma male microvasculature mouse neovascularization (pathology) nonhuman priority journal protein expression protein phosphorylation signal transduction tumor vascularization tumor xenograft weight change animal cancer transplantation chemical model drug antagonism liver tumor metabolism tumor cell line Alanine Animals Apoptosis Carcinoma, Hepatocellular Cell Line, Tumor Cell Proliferation Humans Liver Neoplasms Male Mice Models, Chemical Neoplasm Transplantation Neovascularization, Pathologic Receptors, Fibroblast Growth Factor Receptors, Vascular Endothelial Growth Factor Triazines
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/181019
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-181019
record_format	dspace
spelling	sg-nus-scholar.10635-1810192024-11-10T12:32:26Z Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma Huynh, H Ngo, V.C Fargnoli, J Ayers, M Khee, C.S Heng, N.K Choon, H.T Hock, S.O Chung, A Chow, P Pollock, P Byron, S Tran, E MEDICINE DUKE-NUS MEDICAL SCHOOL basic fibroblast growth factor brivanib alaninate caspase 3 CD31 antigen fibroblast growth factor receptor 1 Ki 67 antigen mitogen activated protein kinase 1 mitogen activated protein kinase 3 protein kinase B vasculotropin vasculotropin receptor 2 alanine brivanib alaninate drug derivative fibroblast growth factor receptor triazine derivative vasculotropin receptor animal experiment animal model animal tissue antiangiogenic activity antiangiogenic therapy antineoplastic activity apoptosis article cancer inhibition cancer model cell proliferation cell strain HepG2 controlled study down regulation drug mechanism drug sensitivity enzyme inhibition human human cell human tissue liver cell carcinoma male microvasculature mouse neovascularization (pathology) nonhuman priority journal protein expression protein phosphorylation signal transduction tumor vascularization tumor xenograft weight change animal cancer transplantation chemical model drug antagonism liver tumor metabolism tumor cell line Alanine Animals Apoptosis Carcinoma, Hepatocellular Cell Line, Tumor Cell Proliferation Humans Liver Neoplasms Male Mice Models, Chemical Neoplasm Transplantation Neovascularization, Pathologic Receptors, Fibroblast Growth Factor Receptors, Vascular Endothelial Growth Factor Triazines 10.1158/1078-0432.CCR-08-0509 Clinical Cancer Research 14 19 6146-6153 2020-10-27T06:55:28Z 2020-10-27T06:55:28Z 2008 Article Huynh, H, Ngo, V.C, Fargnoli, J, Ayers, M, Khee, C.S, Heng, N.K, Choon, H.T, Hock, S.O, Chung, A, Chow, P, Pollock, P, Byron, S, Tran, E (2008). Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clinical Cancer Research 14 (19) : 6146-6153. ScholarBank@NUS Repository. https://doi.org/10.1158/1078-0432.CCR-08-0509 10780432 https://scholarbank.nus.edu.sg/handle/10635/181019 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	basic fibroblast growth factor brivanib alaninate caspase 3 CD31 antigen fibroblast growth factor receptor 1 Ki 67 antigen mitogen activated protein kinase 1 mitogen activated protein kinase 3 protein kinase B vasculotropin vasculotropin receptor 2 alanine brivanib alaninate drug derivative fibroblast growth factor receptor triazine derivative vasculotropin receptor animal experiment animal model animal tissue antiangiogenic activity antiangiogenic therapy antineoplastic activity apoptosis article cancer inhibition cancer model cell proliferation cell strain HepG2 controlled study down regulation drug mechanism drug sensitivity enzyme inhibition human human cell human tissue liver cell carcinoma male microvasculature mouse neovascularization (pathology) nonhuman priority journal protein expression protein phosphorylation signal transduction tumor vascularization tumor xenograft weight change animal cancer transplantation chemical model drug antagonism liver tumor metabolism tumor cell line Alanine Animals Apoptosis Carcinoma, Hepatocellular Cell Line, Tumor Cell Proliferation Humans Liver Neoplasms Male Mice Models, Chemical Neoplasm Transplantation Neovascularization, Pathologic Receptors, Fibroblast Growth Factor Receptors, Vascular Endothelial Growth Factor Triazines
spellingShingle	basic fibroblast growth factor brivanib alaninate caspase 3 CD31 antigen fibroblast growth factor receptor 1 Ki 67 antigen mitogen activated protein kinase 1 mitogen activated protein kinase 3 protein kinase B vasculotropin vasculotropin receptor 2 alanine brivanib alaninate drug derivative fibroblast growth factor receptor triazine derivative vasculotropin receptor animal experiment animal model animal tissue antiangiogenic activity antiangiogenic therapy antineoplastic activity apoptosis article cancer inhibition cancer model cell proliferation cell strain HepG2 controlled study down regulation drug mechanism drug sensitivity enzyme inhibition human human cell human tissue liver cell carcinoma male microvasculature mouse neovascularization (pathology) nonhuman priority journal protein expression protein phosphorylation signal transduction tumor vascularization tumor xenograft weight change animal cancer transplantation chemical model drug antagonism liver tumor metabolism tumor cell line Alanine Animals Apoptosis Carcinoma, Hepatocellular Cell Line, Tumor Cell Proliferation Humans Liver Neoplasms Male Mice Models, Chemical Neoplasm Transplantation Neovascularization, Pathologic Receptors, Fibroblast Growth Factor Receptors, Vascular Endothelial Growth Factor Triazines Huynh, H Ngo, V.C Fargnoli, J Ayers, M Khee, C.S Heng, N.K Choon, H.T Hock, S.O Chung, A Chow, P Pollock, P Byron, S Tran, E Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
description	10.1158/1078-0432.CCR-08-0509
author2	MEDICINE
author_facet	MEDICINE Huynh, H Ngo, V.C Fargnoli, J Ayers, M Khee, C.S Heng, N.K Choon, H.T Hock, S.O Chung, A Chow, P Pollock, P Byron, S Tran, E
format	Article
author	Huynh, H Ngo, V.C Fargnoli, J Ayers, M Khee, C.S Heng, N.K Choon, H.T Hock, S.O Chung, A Chow, P Pollock, P Byron, S Tran, E
author_sort	Huynh, H
title	Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
title_short	Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
title_full	Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
title_fullStr	Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
title_full_unstemmed	Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
title_sort	brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/181019
_version_	1821233883505491968

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

Similar Items